ACCELERON PHARMA INC | 2013 | FY | 3

 

 

 
   Year Ended December 31,  
 
   2013(2)   2012(1)   2011  

Fair value of underlying instrument

     n/a   $ 9.24   $ 6.76  

Expected volatility

     n/a     69.1 %   66.0 %

Expected term (in years)

     n/a     0.16     1.16  

Risk-free interest rate

     n/a     0.04 %   0.12 %

Expected dividend yield

     n/a     — %   — %
(1)
During December 2012, the expiration date of the warrant to purchase Series A Preferred Stock was extended from December 21, 2012 to February 28, 2013.

(2)
The warrant to purchase Series A Preferred Stock was exercised during the three months ended March 31, 2013.

us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock

 

 

 
   Year Ended December 31,  
 
   2013(1)   2012   2011  

Fair value of underlying instrument

   $ 20.03   $ 9.96   $ 7.56  

Expected volatility

     71.2 %   69.1 %   66.0 %

Expected term (in years)

     0.24     0.97     1.98  

Risk-free interest rate

     0.04 %   0.16 %   0.25 %

Expected dividend yield

     — %   — %   — %
(1)
Warrants to purchase Series B Preferred Stock were converted to warrants to purchase common stock at the closing of the IPO on September 24, 2013.

us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock

 

 

 
   Year Ended December 31,  
 
   2013(1)   2012   2011  

Fair value of underlying instrument

   $ 20.03   $ 11.04   $ 8.84  

Expected volatility

     71.2 %   69.1 %   66.0 %

Expected term (in years)

     5.73     6.46     7.46  

Risk-free interest rate

     1.75 %   0.95 %   1.35 %

Expected dividend yield

     — %   — %   — %
(1)
Warrants to purchase Series C-1 Preferred Stock were converted to warrants to purchase common stock at the closing of the IPO on September 24, 2013.

us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock

 

 

 
   Year Ended December 31,  
 
   2013(1)   2012   2011  

Fair value of underlying instrument

   $ 20.03   $ 10.52   $ 8.84  

Expected volatility

     71.2 %   69.1 %   66.0 %

Expected term (in years)

     6.48     7.22     8.22  

Risk-free interest rate

     1.75 %   1.18 %   1.62 %

Expected dividend yield

     — %   — %   — %
(1)
Warrants to purchase Series D-1 Preferred Stock were converted to warrants to purchase common stock at the closing of the IPO on September 24, 2013.

us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock